Drug Patents owned by Commave Therap

1. List of Azstarys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same
Jul, 2032

(9 years from now)

US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 7, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 07 May, 2021

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in